Skip to main content
. 2020 Apr 15;2020:7879629. doi: 10.1155/2020/7879629

Figure 1.

Figure 1

The effects of different concentrations of the caspase-1 inhibitor VX765 on IL-1β and IL-18 levels in CCI and VX765 groups. The levels of (a, c) IL-1β and (b, d) IL-18 in the injured cortex were measured by ELISA and immunohistochemistry 24 h after TBI at different concentrations of VX765 (25, 50, 100, or 200 mg/kg). Note that the levels of IL-1β and IL-18 were significantly decreased for the concentrations of VX765 (100 and 200 mg/kg). At the lowest concentrations of VX765 (25 and 50 mg/kg), there was no significant change in IL-1β or IL-18 compared with the CCI group. Detection on the levels of mNSS (e) and latency to fall (f) through the rotarod test at 24 h after TBI with different concentrations of VX765 (25, 50, 100, or 200 mg/kg) suggested that the mNSS level was decreased and latency to fall was increased in the groups treated with VX765 at the concentration of 50, 100, and 200 mg/kg, and levels of mNSS and latency to fall had no significant difference in the group treated with 25 mg/kg VX765, compared to the CCI group. n = 4. Data are presented as the mean ± SD. ∗∗P < 0.01, ∗∗∗P < 0.001. N.S.: not significant vs. CCI.